Ashwini Arunachalam

10PUBLICATIONS
33CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer diagnosisMedical infection agents (incl. prions)Radiation therapyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 03, 2026
Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study.

|Feb 07, 2026
Rationale and recommendations for improving early-stage oncology diagnosis, treatment, and access.

R Aguiar-Ibáñez, D Goldschmidt, Z Y Zhou

|Jan 28, 2026
Treatment Patterns, Clinical Outcomes, Health Care Resource Use, and Costs in Older Adults with Malignant Pleural Mesothelioma in the United States, 2007-2020.

Himani Aggarwal, Ashwini Arunachalam, Jae Min

|Dec 11, 2025
Real-World Clinical Outcomes and Biopsy Patterns of Older Patients with Unresected Non-Small-Cell Lung Cancer Treated with Primary Stereotactic Body Radiotherapy.

Pragya Rai, Su Zhang, Yan Song

|Nov 19, 2025
Trends in initial primary treatment approach and biomarker testing across social determinants of health in early-stage non-small cell lung cancer.

Xiaohan Hu, Yu-Han Kao, Ashwini Arunachalam

|Oct 20, 2025
A Time and Motion Study Comparing Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab in Combination with Chemotherapy for the Treatment of Metastatic Non-small Cell Lung Cancer.

Erwin De Cock, Sabine Oskar, Cecilia Lourdudoss

Pageof 2

Frequent Collaborators

2 joint publications

Yu-Han Kao

1 joint publications

R Aguiar-Ibáñez

1 joint publications

D Goldschmidt

1 joint publications

O Ciani